Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Therapeutic potential of Withaferin A in cancer-induced muscle and cardiac wasting.

Journal of ovarian research·2025
Same author

Ovarian cancer and the heart: pathophysiology, chemotherapy-induced cardiotoxicity, and new therapeutic strategies.

Journal of ovarian research·2025
Same author

Integrated Analysis of lncRNA-miRNA-mRNA Regulatory Network in Rapamycin-Induced Cardioprotection against Ischemia/Reperfusion Injury in Diabetic Rabbits.

Cells·2023
Same author

Beyond Hepatoprotection-The Cardioprotective Effects of Bicyclol in Diabetes.

Cardiovascular drugs and therapy·2023
Same author

Physiological effects of ivabradine in heart failure and beyond.

Molecular and cellular biochemistry·2023
Same author

Single-Dose Treatment with Rapamycin Preserves Post-Ischemic Cardiac Function through Attenuation of Fibrosis and Inflammation in Diabetic Rabbit.

International journal of molecular sciences·2023
Same journal

Fentanyl and its Analogs: A Medicinal Chemistry Perspective on Therapeutic Potential and Abuse Liability.

Current pharmaceutical design·2026
Same journal

Acne Vulgaris: Integrating Pathophysiology with Conventional, Herbal, and Nanocarrier-Based Therapeutic Strategies.

Current pharmaceutical design·2026
Same journal

Systems Pharmacology and Pharmaco-Transcriptomic Insights into Bauhinia variegata for Polycystic Ovary Syndrome Management.

Current pharmaceutical design·2026
Same journal

Curcumin and Cognitive Health: Insights from Randomized Controlled Trials.

Current pharmaceutical design·2026
Same journal

Inorganic Materials-integrated Porphyrin for Drug Delivery in Cancer Therapy: Promises, Challenges and Outlooks.

Current pharmaceutical design·2026
Same journal

Precision Nanotechnology in Oral Oncology: From Biomarker-Guided Targeting to AI-Driven Theranostics.

Current pharmaceutical design·2026
See all related articles

Related Experiment Video

Updated: May 12, 2026

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

Sildenafil and cardioprotection.

Rakesh C Kukreja1

  • 1Scientific Director, Pauley Heart Center, Professor of Medicine, Physiology, Biochemistry, and Emergency Medicine, Eric Lipman Professor of Cardiology, Division of Cardiology, Box 980204, Virginia Commonwealth University, 1101 East Marshall Street, Room 7-020D, Richmond, VA 23298, USA. rakesh@vcu.edu.

Current Pharmaceutical Design
|April 18, 2013
PubMed
Summary
This summary is machine-generated.

Phosphodiesterase-5 (PDE5) inhibitors, like sildenafil, show significant cardioprotective effects in preclinical studies. These findings suggest potential for novel drug therapies in treating various heart conditions.

More Related Videos

Simultaneous Isolation of High Quality Cardiomyocytes, Endothelial Cells, and Fibroblasts from an Adult Rat Heart
09:38

Simultaneous Isolation of High Quality Cardiomyocytes, Endothelial Cells, and Fibroblasts from an Adult Rat Heart

Published on: May 19, 2017

Related Experiment Videos

Last Updated: May 12, 2026

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

Simultaneous Isolation of High Quality Cardiomyocytes, Endothelial Cells, and Fibroblasts from an Adult Rat Heart
09:38

Simultaneous Isolation of High Quality Cardiomyocytes, Endothelial Cells, and Fibroblasts from an Adult Rat Heart

Published on: May 19, 2017

Area of Science:

  • Cardiology
  • Pharmacology
  • Biomedical Science

Background:

  • Phosphodiesterase-5 (PDE5) inhibitors are established treatments for erectile dysfunction.
  • Sildenafil and tadalafil are also approved for pulmonary arterial hypertension management.
  • Preclinical research indicates broad protective effects of PDE5 inhibitors in cardiovascular conditions.

Purpose of the Study:

  • To explore the potential of PDE5 inhibitors in cardioprotection.
  • To review preclinical evidence supporting PDE5 inhibitors' role in cardiac health.

Main Methods:

  • Review of preclinical studies on PDE5 inhibitors.
  • Analysis of their effects on various cardiac injury models.

Main Results:

  • PDE5 inhibitors demonstrated protective effects against myocardial ischemia/reperfusion injury.
  • These drugs showed benefits in models of heart failure, cardiac hypertrophy, and post-myocardial infarction.
  • Evidence suggests efficacy in Duchenne muscular dystrophy and stem cell preconditioning.

Conclusions:

  • Sildenafil and other PDE5 inhibitors show promise as novel cardioprotective agents.
  • Further development of PDE5 inhibitors for heart disease treatment is warranted.